Bromobutene linagliptin impurity VII is a synthetic byproduct arising from the bromination of a butene moiety during linagliptin API synthesis. It features a brominated conjugated butene backbone linked to a substituted pyrazine-triazole heterocyclic core, with an N-acylated sulfonamide side chain. The compound retains key pharmacophoric elements of linagliptin but incorporates a bromide substituent at the ฮฒ-position of the butenyl bridge, inducing steric and electronic deviations from the parent drug. This impurity serves as an HPLC reference standard for quantifying process-related deviations in linagliptin manufacturing.
 Isomer.png)
